Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

The Valuation of Skillz Stock Remains Excessive

By Larry Ramer, InvestorPlace Contributor

SKLZ stock does not appear to have any of the attributes that investors should look for in names with high valuations.

4 Best Dow Stocks To Buy for September

By Larry Ramer, InvestorPlace Contributor

The following Dow stocks should get a big boost from rapidly approaching macro trends, including fiscal stimulus.

QuantumScape Stock Still High-Risk Against Tough Rivals, High Valuation

By Larry Ramer, InvestorPlace Contributor

With many companies working on advanced EV batteries and QS stock still trading at very high valuations, sell QuantumScape stock.

Fraud Allegations Are Unlikely to Keep Cassava Stock Down

By Larry Ramer, InvestorPlace Contributor

Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy.

Investors Are Underestimating General Electric

By Larry Ramer, InvestorPlace Contributor

GE stock should get a major boost from two bills moving through Congress. These positive catalysts aren't yet reflected in the shares.

Clover Health Stock Is Covered in Red Flags

By Larry Ramer, InvestorPlace Contributor

Facing an SEC investigation and generating mounting losses, while recently reporting the departure of its CFO, Clover's issues make CLOV stock a sell.

Novavax Stock Won’t Have Legs in a Reduced-Covid World

By Larry Ramer, InvestorPlace Contributor

There are signs that the pandemic may end soon, and Novavax has had serious supply issues. As a result, NVAX stock looks too risky.

4 Specialized AI Stocks to Buy for the Boom

By Larry Ramer, InvestorPlace Contributor

Companies with focused AI technologies appear to be doing better than firms with AI based on general data. Here are four AI stocks to buy.

Robinhood Stock Is Going to Take a While to Come Into Its Own

By Larry Ramer, InvestorPlace Contributor

Although Robinhood has strong, longer-term opportunities, the company is facing powerful medium-term challenges. Investors should avoid HOOD stock.

As Fears of the Delta Variant Subside, Pinterest Looks Unattractive

By Larry Ramer, InvestorPlace Contributor

Data indicates that the economic reopening is hurting Pinterest. As a result, PINS stock is unappealing at its current levels.

Load More